Skip to main content

GNTA

Stock

GNTA

Stock
Health Care
Biotechnology

Performance overview

GNTA Price
Price Chart

Forward-looking statistics

Beta
0.27
Risk
88.58%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

Genenta Science SPA is a clinical-stage biotechnology company engaged in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors and cancer. The company's products include Temferon - a product to treat glioblastoma multiforme, a solid tumor affecting the brain, and TEMs -Immuno-Gene Therapy.

Company info

SectorHealth Care
IndustryBiotechnology
Employees14
Market cap$60.1M

Fundamentals

Enterprise value$50.7M
Revenue$0.0
Revenue per employee—
Profit margin0.00%
Debt to equity0.12

Security info

ExchangeNASDAQ
Type of shareADR
Earnings per share (EPS)-$0.58
Dividend per share—
Revenue per share$0.00
Avg trading volume (30 day)$82K
Avg trading volume (10 day)$183K
Put-call ratio—

Macro factor sensitivity

Growth—
Credit—
Liquidity—
Inflation—
Commodities—
Interest Rates—

Valuation

Dividend yield0.00%
PEG Ratio-5.85
Price to sales—
P/E Ratio-5.85
Enterprise Value to Revenue—
Price to book5.56

Upcoming events

Next earnings day—
Next dividend day—
Ex. dividend day—

News

Genenta to Present at Upcoming Scientific and Investor Conferences

MILAN, Italy and NEW YORK, Oct. 05, 2022 ( GLOBE NEWSWIRE ) -- Genenta Science ( NASDAQ: GNTA ) , a clinical stage immune-oncology company developing a cell-based platform harnessing the power of hematopoietic stem cells to provide durable and safe treatments for solid tumors, will present at ...

GlobeNewswire (October 5, 2022)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free